Opens in a new tab

Baqsimi® Nasal Powder Featured in the September 2026 Issue of Nikkei DI

Announcement

Special feature: 「点鼻レスキュー薬、集結。」

Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi® Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI).

Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.

The September issue includes a special feature titled 「点鼻レスキュー薬、集結。」, focusing on nasal rescue medicines used in situations where rapid and practical administration is important.

The feature covers several therapeutic areas, including severe hypoglycemia, epileptic seizures and anaphylaxis, reflecting growing attention to intranasal drug delivery in emergency care.

Within the section on severe hypoglycemia, Nikkei DI introduces Baqsimi® Nasal Powder (glucagon) as a nasal glucagon treatment and presents practical information on its administration in an emergency.

The article includes photographs illustrating the single-use nasal device and the administration procedure, helping provide healthcare professionals with a practical overview of how the product is used.

For GRP Japan, the inclusion of Baqsimi® in this professional feature provides an opportunity for healthcare professionals to learn more about severe hypoglycemia and its management.

PublicationNikkei Drug Information (Nikkei DI)
IssueSeptember 2026
Special Feature「点鼻レスキュー薬、集結。」
Featured GRP ProductBaqsimi® Nasal Powder

Marketing Authorization Holder in Japan: Global Regulatory Partners GK

Source: Source: Nikkei Drug Information, September 2026 issue.
Cover image reproduced with permission of the publisher.
Baqsimi® is a registered trademark of its respective owner.

Related News

  • GLOBAL REGULATORY PARTNERS JAPAN JOINS THE TOKYO CHAMBER OF COMMERCE AND INDUSTRY (TCCI)

    Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Tokyo Chamber of Commerce and Industry (TCCI / 東京商工会議所), effective October 2026. GRP Japan will belong to the Minato Branch (港支部), one of TCCI’s 23 ward-based branches, strengthening the company’s connection with the local business community in Minato Ward.
  • Global Regulatory Partners Announces MHLW Approval of Aflibercept Biosimilar Prefilled Syringe in Japan

    Tokyo, Japan - October 26, 2026 - Global Regulatory Partners GK (GRP) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on October 13, 2026 for Aflibercept BS Solution for Intravitreal Injection Kit 40 mg/mL [GRP] (prefilled syringe (PFS) presentation), a biosimilar to EYLEA®¹ (aflibercept), for ophthalmic use.
  • GRP JAPAN JOINS THE JAPAN RADIOPHARMACEUTICALS ASSOCIATION

    Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.
  • Global Regulatory Partners to Exhibit at BioJapan  2026

    Global Regulatory Partners (GRP) is pleased to announce its participation in BioJapan  2026, where GRP will exhibit at Booth C-41 and participate in the event's international Partnering program. BioJapan  2026 is observing its 40th anniversary as the world’s longest running biotechnology event.  It is held together with concurrent events,Regenerative Medicine JAPAN, and healthTECH JAPAN, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.